Virginia Commonwealth University

VCU Scholars Compass
Theses and Dissertations

Graduate School

2010

The Mechanism of Obesity in Rai1+/- Mice
Kristie Schmidt
Virginia Commonwealth University

Follow this and additional works at: https://scholarscompass.vcu.edu/etd
Part of the Medical Genetics Commons
© The Author

Downloaded from
https://scholarscompass.vcu.edu/etd/135

This Thesis is brought to you for free and open access by the Graduate School at VCU Scholars Compass. It has
been accepted for inclusion in Theses and Dissertations by an authorized administrator of VCU Scholars Compass.
For more information, please contact libcompass@vcu.edu.

© Kristie Schmidt, 2010

All Rights Reserved

The Mechanism of Obesity in Rai1+/- Mice
A thesis submitted in partial fulfillment of the requirements for the degree of Master of Science
at Virginia Commonwealth University.

by

Kristie Schmidt
Bachelor of Science (B.S.)
Saint Norbert College, 2004

Director: Sarah H. Elsea, Ph.D., F.A.C.M.G.
Associate Professor, Departments of Pediatrics and Human and Molecular Genetics

Virginia Commonwealth University
Richmond, Virginia
August, 2010

Acknowledgement
I would like to thank Dr. Sarah H. Elsea for giving me the amazing opportunity to be a
part of her lab. She has been a supportive and knowledgeable advisor and her guidance and
advice have made me a better person, student, and scientist. I would also like to thank the Elsea
lab members for all of their help in supporting my research and for all of their patience and
support in teaching me new techniques. I want to specifically thank Stephen Williams for all of
the effort he put forth in teaching me to be a successful member of the Elsea lab. He was always
available for questions and concerns and made everyone in the lab feel as though the work they
were doing was important to him. I would like to thank previous Elsea lab member Brooke
Burns for all of her support and friendship. She has been living across the country but is still
available if I ever need any assistance with interpreting mouse data. I have appreciated the help
of Meghan MacNeal and wish to thank her for her support and dedication to the Elsea lab and the
mouse colony. I would also like to thank the current lab members: Sureni Mullegama, Anam
Bashir, Sun Kim, Catie McConnell, Saba Chhotani, and Danielle Bartholomew for their support
and friendship. These lab members were always willing to help when I needed some assistance
and made the lab a very fun and productive place to work. I would like to thank John Moore and
Dr. Patrick Sachs for all of their lab help and support.
I would like to thank Dr. Brien Riley, Dr. Jenny Wiley, and Dr. Jolene Windle for being
on my committee and for all of their support and suggestions which have made me a better
scientist. I would also like to thank the University of Cincinnati Mouse Metabolic Phenotyping
Core, Ms. Manavi Johri for technical assistance, and Dr. J. Almenara, Dr. H.D. Massey, and C.
Minard-Wilson for assistance with histology. I would also like to thank the Vanderbilt University
Mouse Metabolic Phenotyping Center for a quick turn-around of serum level data. Thank you to
i

Cortex Pharmaceuticals for use of an ampakine drug for pilot studies. Dr. Robert Vann and Mary
Tokarz were involved in data collection of the ampakine study.
I would lastly like to thank my family and friends. Without your support I would never
have been able to pursue my dreams and goals. My parents, grandparents, and siblings have been
an amazing support system that I have counted on for many things during my stay at VCU. They
have always believed in me and their support, both emotionally and financially, has been
unmatched.

ii

Table of Contents

List of Tables………………………………………………………………………..v
List of Figures……………………………………………………………………….vi
Abstract…………………………………………………………………………….. vii

Chapter 1: Literature review of Smith-Magenis syndrome………………………....1
Introduction………………………………………………………………….……... 1
Rai1 gene……............……………………………………………………….……...1
RAI1 role in SMS................................……………………………………….……..2

SMS phenotypes..…………………………………………………………………...3
Mouse model of SMS........................……………………………………………….4
Chapter 2: The mechanism of obesity of Rai1+/- mice…………………………......5

Introduction................................................................................................................ 5
Methods……………………………………………………………………………..7

Results……………………………………………………………………………… 12

I.

Eating behavior and obesity..................................................................... 14

iii

II.

Metabolic syndrome and the Rai1+/- mouse model................................ 18

III.

Metabolic signaling from adipose tissue to hypothalamus...................... 23

Discussion……………………………………………………………………….......30
Chapter 3: Ampakine treatment of Rai1+/- mice........................................................ 33
Introduction………………………………………………………………………… 33
Methods…………………………………………………………………..…………34
Results……………………………………………………………………..……...... 39
Discussion………………………………………………………………..………….53
Conclusions and future plans………………………………………………..............57
Bibliography…………………………………………………………………….…..57

Vita............................................................................................................................. 62

iv

List of Tables

Table 1. Data of reflexes and behavior testing in ampakine treated Rai1+/and WT mice…………………………………………………………………………....40

v

List of Figures

Figure 1. WT and Rai1+/- mouse body weights...............................................................12
Figure 2. Photograph of SMS mouse model....................................................................13
Figure 3. Satiety of WT and Rai1+/- mice after a 24 hour fast.........................................17
Figure 4. Distribution of adipose tissue in Rai1+/- and WT mice.....................................20
Figure 5. Serum levels of blood glucose, triglycerides, and total cholesterol…………..22
Figure 6. Serum levels of hormones involved in satiety and energy metabolism............26
Figure 7. mRNA expression studies................................................................................ 29
Figure 8. Mechanistic pathway of satiation in the hypothalamus...................................32
Figure 9. Gating tests and drop test of ampakine and vehicle injected mice.................41
Figure 10. Hot plate test of ampakine and vehicle treated Rai1+/- and WT mice...........42
Figure 11. Rotorod and motor activity of ampakine and vehicle treated Rai1+/and WT mice....................................................................................................................43
Figure 12. Behavioral testing over a 5 minute period of ampakine treated WT
and Rai1+/- mice…………………………………………………………………………45
Figure 13. Operant test of ampakine and vehicle treated Rai1+/- and WT mice..............46
Figure 14. Growth curve of C57Bl/6J:FVB/N mice……………………………………49
Figure 15. Food consumption and weight of ampakine and vehicle treated Rai1+/and WT mice....................................................................................................................50
Figure 16. Blood glucose of ampakine and vehicle treated Rai1+/- and WT mice......... 52

vi

Abstract

The Mechanism of Obesity in Rai1+/- Mice
A thesis submitted in partial fulfillment of the requirements for the degree of Master of Science
at Virginia Commonwealth University.

by
Kristie Schmidt
Bachelor of Science (B.S.)
Saint Norbert College, 2004

Director: Sarah H. Elsea, Ph.D.,F.A.C.M.G.
Associate Professor, Departments of Pediatrics and Human and Molecular Genetics

Smith-Magenis syndrome (SMS) is a genetic disorder caused by a deletion or mutation
of the retinoic acid induced 1 (RAI1) gene on chromosome 17p11.2 that results in
haploinsufficiency. SMS patients with a deletion account for 90% of the cases, while the other
10% have a mutation in RAI1. The syndrome is characterized by cognitive impairment,
craniofacial abnormalities, sleep disturbances, developmental delay, obesity, and behavioral
phenotypes. SMS is thought to affect 1:25,000 live births, although due to similar infantile
phenotypes with Down syndrome and Prader-Willi syndrome, SMS may be mis- or underdiagnosed. In a study of 54 children, it was shown that by age 12, females with SMS are in the
90th weight percentile, while males reach the 90th percentile by age 14. It was also shown that
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teens and adults with Smith-Magenis syndrome commonly present with truncal obesity. In order
to keep SMS patients healthy, to reduce the risk for future health problems associated with
obesity, and to more fully understand the role of Rai1 in Smith-Magenis syndrome, it is first
necessary to understand the mechanism by which SMS patients become obese. Mouse models of
SMS provide a powerful tool for looking at potential mechanisms of obesity related to the
haploinsufficiency of Rai1. Obesity in Smith-Magenis syndrome may result from a combination
of I) behavioral, II) metabolic, and III) signaling mechanisms in which the haploinsufficiency of
Rai1 causes deviations in critical pathways responsible for energy intake and expenditure. Data
suggest that the Rai1+/- mice are obese and hyperphagic. Data also demonstrate that Rai1+/- mice
do not have symptoms of metabolic syndrome associated with their obesity. Signaling
mechanisms are deviated from normal in Rai1+/- mice, including leptin levels and the expression
of Pomc, Mc4r, Bdnf, and Agrp. Treatment with ampakine drug may increase expression of Bdnf
and help to control obesity in Rai1+/- mice.

viii

Chapter 1: Background and Literature Review

Smith-Magenis syndrome (SMS) is a genetic disorder caused by a deletion or mutation
of the retinoic acid induced 1(RAI1) gene on chromosome 17p11.2 that results in
haploinsufficiency.1,2,3 SMS patients with a deletion account for 90% of the cases, while the
other 10% have a mutation in RAI1.1 The syndrome is characterized by cognitive impairment,
craniofacial abnormalities, sleep disturbances, developmental delay, obesity, and behavioral
phenotypes.4,5 SMS is thought to affect 1:25,000 live births, although due to similar infantile
phenotypes with Down syndrome and Prader-Willi syndrome, SMS may be mis- or under
diagnosed.5.6

RAI1 Gene
The RAI1 gene was first discovered in mouse carcinoma cells when it was shown that
RAI1 expression is upregulated by retinoic acid.7 RAI1 was first shown to be localized to
neurons and later found to be expressed in almost all tissue types, with increased levels found in
neuronal structures and the heart.3,7,8,9 Expression of RAI1 is ubiquitous with the exception of a
portion of the brain responsible for cerebral hemisphere communication called the corpus
callosum because it consists mainly of axonal projections.8,10 RAI1 maps to the SMS critical
region located on chromosome 17p11.2 and is highly conserved among mammals, with the
human and mouse RAI1 genes sharing 84% homoology.8,11 The gene contains 6 exons and
encodes an 8.5 Kb mRNA.8,11 The RAI1 gene contains a CAG repeat that encodes a glutamine
repeat, two bipartite nuclear localization signals, and a zinc finger plant homeo domain(PHD).8
A 1906 amino acid protein is encoded by the RAI1 gene, with a molecular weight of ~203kD.8
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The human RAI1 protein is 84% identical to the mouse Rai1 protein, with 88% similarity.11
One difference between the mouse and human proteins is a variation in the polyglutamine repeat,
as the human protein contains 10-18 glutamate residues while the mouse Rai1 only contains 4.8
Mouse Rai1 does not include a polyserine domain that is present only in the human RAI1
protein.8
RAI1 is localized to the nucleus and is thought to function as a transcription factor,
although specific functions are unknown. The zinc finger PHD has been found in proteins that
are involved in chromatin-mediated transcriptional regulation, and is thought to mediate
protein-protein interactions that regulate transcription through a complex consisting of many
integral parts.12,13,14 In addition, RAI1 demonstrates significant homology to the transcription
factor TCF20.8 Rai1 recombinant protein has also been shown to have transactivation activity
and therefore acts as a transcriptional element most likely through chromatin remodeling.14

RAI1 role in SMS
A deletion of chromosome 17p11.2 is responsible for 90% of Smith-Magenis
syndrome cases while the remaining 10% of cases are due to mutation of RAI1.15 It is reported
that of the deletion cases, 75% of SMS patients share a ~3.5Mb common deletion, while the
remaining 25% have smaller deletions on chromosome 17p11.2 including RAI1.9 The common
deletion is prevalent due to low copy repeats known as REPs that are found flanking RAI1. The
minimum deletion region is approximately 700 kb in size.11 These repeats can undergo nonallelic homologous recombination during meiosis, which results in a deletion of the portion of
chromosome 17, lying between the proximal and distal REPs.16 Mutations in the RAI1 gene can
also lead to Smith- Magenis syndrome.3,11,13,17 It is demonstrated that virtually all cases of SMS
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occur de novo, which suggests a low recurrence for parents to pass it on to other offspring.2
There is, however, evidence that some parents are mosaic carriers, passing their deletions on to
their children.18 These mosaic carriers have the deletion in only some of their cells and therefore
do not present with symptoms of SMS but may still pass it to their children. The deletion can
come from either parental gamete randomly without difference in phenotype and therefore,
suggests that imprinting does not play a role in SMS.2

SMS phenotypes
Some of the most prevalent SMS phenotypes include failure to thrive as infants,
peripheral neuropathy, speech delay, sleep disturbance, cognitive impairment, craniofacial
abnormalities, short stature, obesity, self-injurious and other behavioral phenotypes.2,5 When
SMS patients are babies, their parents often consider them to be the perfect baby. Mothers often
experience 50% less fetal movement in pregnancies.19
Approximately 75% of SMS patients have peripheral neuropathy including decreased
sensitivity to pain, as well as temperature. This likely contributes to 92-98% of SMS patients
exhibiting several self-injurious behaviors.5,20 These behaviors include: head-banging, wristbiting, skin picking and pinching. Two phenotypes that are unique to SMS are
onychotillomania, defined as nail picking, as well as polyembolokolamania, which is the habit of
inserting foreign objects into body openings.2 Another unique behavioral aspect of SMS is the
self-hug that becomes more frequent when the individual is pleased and happy. This behavior
tends to also be linked with the repetitive hugging of others.21 It is suggested that 60-80% of
patients with SMS also display aggression, have temper tantrums, and exhibit attention seeking
behaviors.1,6

3

Speech delay occurs in 96% of SMS cases along with cognitive impairment.6 Most
individuals with SMS have an I.Q. ranging from 20-78.6 It is also shown that they have a weak
short-term memory but are excellent at long-term memory and visual reasoning.22
Sleep disturbance is another common phenotype that is reported in 75-100% of
patients.15 SMS patients complain of short total sleep time and are prone to frequent
awakenings.2 These sleep disturbances are associated with an inversion in the circadian rhythm
of melatonin.23 Melatonin is a hormone that is responsible for inducing sleep and peaks in the
middle of the night. A study of SMS patients indicated that their melatonin levels peak during
the day instead of during the night and cause many problems for sleeping and behavior.23 It is
thought that the abnormalities in their sleep patterns may contribute to some of the behavioral
issues in SMS patients. SMS patients that were treated with beta(1)-adrenergic antagonist, a
compound that suppresses the secretion of melatonin, experienced improved sleeping habits and
behavior.24

Mouse model of SMS
The human chromosome 17p11.2 is syntenic to a 32-34 cM region on mouse
chromosome 11. An Rai1+/- mouse was created by replacing a 3910 bp portion of exon 2 with a
vector that contained an E. coli lacZ and neoR expression cassette.14 This inserted vector results
in a truncated Rai1 protein and loss of the nuclear localization signals and PHD domain and is
therefore not functional. These Rai1+/- haploinsufficient mice are characterized by having lower
weights at birth, as seen in human cases of SMS, and become obese by 20 weeks of age.14
Homozygosity for the Rai1 knockout allele results in embryonic lethality. The Rai1+/- mice
commonly have problems with breeding.
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Chapter 2: The mechanism of obesity of Rai1+/- mice
Introduction
Obesity, defined as having a body mass index (BMI) of greater than 30, has been a
growing concern in the United States, and as of 2008, approximately 35% of American adults
were considered obese.25 According to the American Academy of Child and Adolescent
Psychiatry, between 16-33 percent of children are also obese. As stated earlier, both SMS
patients and Rai1+/- mice demonstrate obesity as a common phenotype.4,14 In a study of 54
children with SMS, it was shown that females are in the 90th weight percentile by age 12, while
males reach the 90th percentile by age 14.26 It was also shown that teens and adults with SmithMagenis syndrome commonly present with truncal obesity.4 In addition to obesity, 57% of SMS
patients are reported to have hypercholesterolemia.27 Most patients with SMS not only have
RAI1 deleted, but also have the closely linked gene sterol regulatory element binding protein 1
(SREBF1) deleted. This gene is a transcription factor that is involved in cholesterol homeostasis,
as it controls the LDL receptor.27 Variations in this gene are shown to be associated with insulin
resistance, type 2 diabetes and glycemia.28 It is also stated that obese people display more
emotionally induced eating behavior than nonobese people do.29 The obesity phenotype in
combination with these above mentioned risk factors make the obesity phenotype in SMS
patients an important avenue of study. In order to keep SMS patients healthy, to reduce risk for
future health problems associated with obesity, and to more fully understand the role of RAI1 in
Smith-Magenis syndrome, it is first necessary to understand the mechanism by which SMS
patients become obese. Obesity in Smith-Magenis syndrome may result from a combination of
I) behavioral, II) metabolic, and III) signaling mechanisms in which the haploinsufficiency of
RAI1 causes deviations in critical pathways responsible for energy intake and expenditure.
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Mouse models of SMS provide a powerful tool for looking at potential mechanisms of obesity
related to the haploinsufficiency of RAI1.
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Materials and Methods
Mice, breeding, and maintenance. Rai1 heterozygous mice that have been previously reported
as B6.129S7-Rai1tm1Jrl/J were purchased from Jackson Laboratories (stock #005981). The mice
were then backcrossed with C57Bl/6J-Tyrc-2J/J for more than 10 generations to create a congenic
background. This strain, referred to as Rai1+/-, was bred in-house with C57Bl/6J mice unless
otherwise noted. Mice were given unrestricted access to water and to a standard fat (5.7%) diet
(Harlan Teklad LM-485 7012) ad libitum. When the mice were being bred or in feeding studies,
they were given access to a higher fat (9%) Lab Diet 5P06 Prolab RMH 2000 diet and water ad
libitum. An automatic 12-hour light/dark cycle was provided at all times along with constant
temperature (21°C) and humidity (40%). All testing was carried out during the light portion of
the cycle except for evening feeding studies. Any night testing was done under the use of red
light to maintain a consistent light/dark cycle. All animals were housed in compliance with the
guidelines of the IACUC at Virginia Commonwealth University.

Genotyping. DNA was extracted from tails as described previously in Girirajan et al., 2008.
Rai1+/- genotypes were confirmed using target allele and wild type primers as reported in Bi et
al., 2005. Minor changes were made to the PCR conditions for optimal genotyping. Four uL of
BSA (1 mg/mL) were added per 25 uL reaction. The cycling conditions used were 95°C for 15
minutes for 1 cycle, 42 cycles of 95°C for 30 seconds, 60°C for 1 minute, 72°C for 1 minute,
followed by an extension at 72° C for 7 minutes.

Light phase and fasting feeding studies. Male mice of each genotype (Rai1+/- and wild type)
were placed in isolated cages with a predetermined amount of higher fat food (9% fat) and an
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unlimited amount of water. Food was weighed every 12 hours for 3 days. Night measurements
were taken under a red lamp. To fast animals, all food was removed for 24 hours and animals
were placed in a new cage to prevent food left on the cage floor from being eaten. After 24
hours, a predetermined amount of food was returned at the beginning of the light phase.
Measurements were then taken every 12 hours for 3 days. These evaluations were performed at
5, 10, 15, and 20 weeks of age.

Revised light phase and fasting feeding studies. Female and male mice of each genotype
(Rai1+/- and wild type) were placed in isolated cages with a predetermined amount of food (9%
fat) and an unlimited amount of water. Food was weighed every 12 hours for 2 days. All night
measurements were taken using a red lamp. Mice were then fasted for 24 hours by removing
food and placing them into a new cage to prevent food left on the cage floor from being eaten.
Upon completion of the fast, the mice were given a predetermined amount of food during the
beginning of the light cycle. Food measurements were taken every 12 hours for 2 days. The
mice were 5, 10, 15, >25 weeks of age during these studies.

Blood glucose. Blood was taken from the tip of each mouse tail using a needle stick and
measured using capillary test strips and an Easy Pro glucometer. All glucose samples were taken
after a 12 or 24 hour fast.

Fat distribution patterns in Rai1+/- mice. (Protocol adapted from Brooke Burns' thesis (2009).)
Fat distribution in Rai1+/- mice was determined via dissection. Male and female mice were
selected with age matched wild type animals at varying ages and euthanized via a CO2 chamber.
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The mice were weighed and intra-abdominal fat pads (gonadal, retroperitoneal, and mesenteric)
and subcutaneous fat pads (dorsal, inguinal and groin) were collected via dissection and
weighed.30 From female mice, fat was also collected from the chest cavity when present.
Weight measurements of both abdominal and subcutaneous fat pads were combined to determine
the amount of total fat collected.

Mouse videotaping. Mice of both Rai1+/- and WT genotypes were age-matched (if possible)
and placed in fresh cages. The mice were then given food and water ad libitum and videotaped
for varying amounts of time using a tripod mounted camcorder.

Serum analysis. For samples that required fasting conditions (triglycerides, total cholesterol,
GLP-1, corticosterone, ACTH, ghrelin, IGF-1, PYY, and amylin), blood was collected from the
facial vein under general anesthesia with isofluorane after a fasting period of 24 hours. Required
additives for each assay were added immediately following blood collection. A 1X protease
inhibitor cocktail (Roche) was added for amylin measurements, and the serine protease inhibitor
(AEBSF) 4-(2-amino-ethyl)benzenesulfonyl fluoride hydrochloride (Sigma) was added (.4
mg/mL) for ghrelin measurements. Serum samples were aliquoted and stored at -20ºC. ELISA
tests were performed at the University of Cincinnati Mouse Phenotyping Core per standard
protocols. Serum levels were performed at the Vanderbilt University Mouse Metabolic
Phenotyping Center.

Histological analysis. For paraffin histology, abdominal adipose tissues isolated from the same
anatomical region from age matched Rai1+/- and wild type females were fixed in 4%
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paraformaldehyde in phosphate-buffered saline. The tissues were processed using a Tissue-Tek
VIP 5 tissue processor (Sakura Finetek USA, Torrance, CA) and then embedded in paraffin
blocks. Paraffin blocks were cut into 5 µm sections and then processed using standard
deparaffinization and rehydration techniques. Sections were mounted on silanized glass slides
and stained with hematoxylin and eosin using a Tissue-Tek Prisma Automated slide stainer
(Sakura Finetek USA, Torrance, CA).

Hypothalamus isolation. Male and female 30 week old wild-type mice were euthanized by
CO2 exposure. Hypothalami were extracted from >25 week old mice for qPCR expression.
Hypothalami were immediately extracted from mouse brains, flash frozen in dry ice and stored at
-80°C.

RNA isolation: RNA was isolated using the Trizol Reagent/chloroform isolation method. A
DNase treatment was also implemented during the RNA isolation using standard protocols and
DNase from Promega. The quality of the isolated RNA was determined using a 260/280
absorbency ratio and concentration determined using a Thermo Scientific Nanodrop 1000.

Real-time quantitative PCR. RNA was extracted from the hypothalami of male and female
mice of several ages using the Trizol reagent/chloroform method and the concentration assessed
by nanodrop. cDNA synthesis was carried out using 2.75-5 µg of RNA, Invitrogen Superscript 2
reverse transcriptase and oligo primers according to the manufacturer‟s instructions. ABI
Taqman probes for mouse mRNA expression were used to detect gene expression for Pomc,
Mc4r and Agrp. All samples were run three times and in triplicate in a 10 µL reaction using the
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Standard 7500 setting on a ABI Prism 7500 Fast System with mouse Gapdh as an endogenous
control.

Statistics. All statistical methods were conducted using JMP or Prism Graphpad 4.0 software.
Mean food consumption at 5, 10, 15, 20, and 25 weeks were compared using pooled data from
12 different isolated feeding studies and dependent on genotype and age. These data were
compared among the 2 genotypes (WT and Rai1+/-) using ANOVA. Food intake after the 24
hour fast (taken at 2-48 hours) was evaluated using repeated measures ANOVA, with effects for
individual mouse, genotype, time point, and group time interaction. These data were also
evaluated separately for each time point using ANOVA. Analyses of feeding data done by
Brooke Burns. The average proportion of food consumed at night was evaluated using repeat
measures ANOVA. Student t-tests were used to compare serum levels as well as mRNA
expression levels.
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Results
Obese Rai1+/- mice
While most adult Bl/6 mice weigh approximately 35 grams at >30 weeks of age, the
Rai1+/- mice weigh 50-65 grams (p<0.0001 Figure 1a, b, Figure 2). Data from Figure 1
partially collected by Brooke Burns. It has been previously determined that Rai1+/- pups
between the ages of 4 and 7 weeks are underweight.14 Mice weights were taken at various ages
to demonstrate that Rai1+/- pups at 5 weeks of age are smaller than their WT littermates but
begin to catch up in weight at 20 weeks of age (p=0.0025, Figure 1a, b). This weight
fluctuation is seen starting at about 15 weeks. From 15 weeks of age, the slope of weight gain is
much steeper for the Rai1+/- mice. Once the mice reach 20 weeks of age, the Rai1+/- males are
significantly heavier ( p=0.0359, Figure 1b) than their WT littermates, and this significance
continues past 30 weeks of age for both sexes, as the mice still have increasing weights.
a.

b.

Male Body Weight

Female Body Weight
80.0

80.0

WT
Rai1+/-

60.0

Weight (g SEM)

Weight (g SEM)

***

40.0

20.0

0.0

***
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Rai1+/-

60.0

*
*

40.0

*
20.0

0.0
5
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30+

5

10
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20
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Age (Weeks)
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Figure 1. WT and Rai1+/- mouse body weights. a) Body weights for female WT and Rai1+/mice from 5-30+ weeks. b) Body weights for male WT and Rai1+/- mice from 5-30+ weeks.
Data plotted as mean  s.e.m.; n  3. *P<0.05, ***P<0.0001.
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a.

b.

WT

Rai1+/-

Figure 2. Photograph of SMS mouse model. a) Photograph of WT and Rai1+/- female mice at
47 weeks of age. b) Photograph of Rai1+/- female 54 weeks of age from a 50:50 mixed
background of C57Bl/6J:129/SvJ .
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I. Eating Behavior and Obesity
To illuminate behavioral aspects that play a role in the obesity of SMS patients and the
Rai1+/- mouse model, it was necessary to look at overall food consumption. It is of importance to
note that food hoarding has been associated with SMS patients.15 Similar behavior is seen in the
mice, as many bits of food can be found in the bottom of Rai1+/- mice cages. These eating
behaviors may alter the reliability of the feeding data. Upon attempting to correct for the messy
eating behavior, several pieces of food were removed from the bottom of the Rai1+/- cages with
the intention of correcting the feeding study data by subtracting an averaged amount of food on
the bottom of each Rai1+/- mouse cage. This correction was not accurate and was not used, as the
Rai1+/- mice did not consume food in the same manner. Some of the mice retained large portions
of food in their cages while others had a layer of pulverized pieces in their cages which were
unable to be weighed accurately as separation from bedding was impossible.
Using isolated feeding studies, it was concluded that Rai1+/- male mice eat significantly
more food than their WT littermates at 20 weeks of age and continue this behavior the rest of
their adult lives.31 This demonstrates hyperphagia is a contributing factor to the obesity seen in
the Rai1+/- mice. The increased consumption is important in helping the small Rai1+/- pups grow
to be an equivalent weight to their WT littermates at 20 weeks, as it has been previously reported
and shown in Figure 1.14 The increased eating behavior was also thought to be responsible for
the continued weight gain seen in the Rai1+/- mice. Previous data also show that the male Rai1+/mice only consume more food than their WT littermates at 20 weeks of age when their individual
weights are accounted for.31 For this data, the amount of consumed food was divided by the
weight of each individual mouse to determine the amount of food eaten per weight of the animal.
These data, although suggesting hyperphagia, do not account for continued weight gain as the
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mice age, because their food consumption by weight is not significantly different from their WT
littermates at 25 weeks of age.31
In order to better understand why the mice still gain weight even though they are not
consuming more food per body weight and to illuminate other food behaviors that are important
in determining the obesity pathway in SMS, a satiety response to food consumption was
evaluated. Data were taken from both female and male mice during fasting feeding studies (see
Materials and Methods). A portion of the male feeding studies were completed by Brooke
Burns. The trends for the female mice were not significantly different between age groups so
mice were pooled for satiation results (5,10, >25 weeks). Male satiety data were taken from
mice at 20 weeks of age.
Pre-fast feeding behavior was compared to each 12 hour food measurement post-fast
using a two-tailed unpaired t-test. Data show that WT males that are fasted for 24 hours do not
consume more food at 12 hours post fast compared to their pre-fast eating. There is, however, a
trend suggesting slightly elevated food consumption in these mice. The male WT mice then
consume a significantly lower amount of food at 24 hours and 36 hours post fast compared to
pre-fast food consumption (p = 0.0051 and 0.0349, Figure 3a). Although the WT female mice
have a similar trend, the only significant difference in food consumption post-fast compared to
pre-fast was at 12 hours (p = 0.0060, Figure 3b). The female WT mice consumed an increased
amount of food directly after fasting followed by a similar trend to WT males of reduced
consumption even though it is not significant. Rai1+/- males and females exhibit no satiation
response, as none of the food consumed post-fast was significantly increased or decreased
compared to pre-fast feeding behavior (Figure 3. c, d). These data show that although they may
be hyperphagic, it is not necessarily correlated to satiety, as Rai1+/- mice do not have a
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significant satiety response that is controlling energy intake. This is made very evident in the
feeding behavior of a Rai1+/- female mouse as her maximum weight was 84 grams. Upon
fasting, this female chewed on the metal bars of her fresh cage indicating that she may not only
be exhibiting a hunger response but also repetitive behavior that is similarly demonstrated in
some patients with SMS.15
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3. Satiety of WT and Rai1+/- mice after a 24 hour fast. a) 20 week old male WT mice feeding
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II. Metabolic syndrome and the Rai1+/- mouse model
It is important to determine not only the behavioral phenotypes associated with obesity
but also the underlying causes and metabolic phenotypes. As stated earlier, truncal obesity is
common in SMS patients and evidence supports that centrally distributed obesity correlates
strongly with increased risk of metabolic syndrome.32 A patient survey done by Brooke Burns of
the Elsea lab indicated that of 32 SMS patients under the age of 19, 40.6% had truncal obesity,
while 45% of adults with SMS in this cohort were obese. According to the National Health and
Nutrition Examination Survey (NHANES) approximately 16.9% of children ranging from 2-19
years of age were obese in 2007-2008. Truncal obesity is increasingly prevalent among patients
with SMS when compared to the national average.
Metabolic syndrome is characterized by a number of risk factors that increase an
individual's risk for atherosclerotic cardiovascular disease and type II diabetes mellitus.33 Some
of these risk factors include obesity, insulin resistance, hypertension, high cholesterol, and high
triglycerides.33 These risks start in childhood and it is suggested that metabolic syndrome is
difficult to associate with causes as there are several genetic and environmental aspects
involved.34 The patient survey done by the Elsea lab also indicated that out of 32 patients that
were 19 years of age or younger, one had high triglycerides and three had high cholesterol. Of
adults in this survey, two of them had type II diabetes mellitus, two had high cholesterol, and two
had high triglycerides. These risk factors for metabolic syndrome are less prevalent in SMS
patients when compared to the general population, but may not always be present due to a
change in lipid metabolism which can cause atherosclerosis though triglyceride levels are
normal. A 32 year old SMS patient presented with atherosclerosis and a stroke without having
other metabolic syndrome risk factors such as type II diabetes or high blood pressure.35 Studying
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metabolic syndrome in a genetic disorder that causes an obesity phenotype, such as SMS, may
help to elucidate the key players in adolescent obesity.

Adiposity in Rai1+/- mice
As stated above, most SMS individuals carry their extra weight around their abdomen.
To determine if this same fat distribution is found in the Rai1+/- mice, analyses were done to
determine the anatomical location of the adipose tissue as well as the type of fat that makes up
the excess adiposity. Adult Rai1+/- and WT mice, >25 weeks old, were dissected, and fat was
strategically removed from common adipose deposits of the mouse anatomy (see Methods and
Materials, some data collected by Brooke Burns). The total amount of fat was weighed from
each mouse and showed that there was significantly more fat in the Rai1+/- female mice than
their WT littermates (p = 0.0009, Figure 4a). This is most likely due to the increased weight
seen in the Rai1+/- female mice compared to their WT littermates. White adipose tissue was
found inside the thoracic cavity in addition to the excess abdominal fat found in the Rai1+/female mice. There was no difference in amount of fat collected between Rai1+/- and WT male
mice (Figure 4a). Once the total amount of fat was extracted and weighed, it was important to
determine if the Rai1+/- mice have more abdominal or subcutaneous fat. As stated earlier,
metabolic syndrome is correlated with abdominal and central obesity. Rai1+/- female mice were
shown to have significantly more abdominal fat in proportion to subcutaneous fat than their WT
female mice (p < 0.0001, Figure 4b). The Rai1+/- and WT male mice did not have significant
differences in the proportion of abdominal to subcutaneous fat (Figure 4c). Due to an increased
amount of fat present in the Rai1+/- mice, a histological analysis was done to determine the
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make-up of the white abdominal adipose tissue. H&E staining indicated no difference in cell
shape or size between Rai1+/- and WT female adipose tissue samples (Figure 4d).
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Figure 4. Distribution of adipose tissue in Rai1+/- and WT mice. a) Total amount of fat (by
weight) collected from each genotype. b) Rai1+/- and WT female proportions of subcutaneous
and abdominal fat. c) Rai1+/- and WT male proportions of subcutaneous and abdominal fat. d)
H&E staining of abdominal adipose tissue of Rai1+/- and WT adult 40 week old female mice.
Analyzing the tissue slides with a 20X objective reveal no significant differences between
adipocytes from Rai1+/- and WT mice. Data plotted as mean  s.e.m.; n ≥ 3 ***P<0.0001.
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To determine if the Rai1+/- mice have any other risk factors for metabolic syndrome,
serum levels of blood glucose, triglycerides, and total cholesterol were measured. Elsea lab data
previously showed that serum insulin levels were not significantly different between Rai1+/- and
WT mice, suggesting that the mice do not have type II diabetes. These results were confirmed
with non-significant differences in blood glucose between Rai1+/- and WT mice (Figure 5a).
Both triglycerides and total cholesterol were not significantly different among Rai1+/- and WT
mice (Figure 5b, c). All of the serum levels were tested by gender, age, and weight and not
significant for any of those factors.
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Figure 5. Serum levels of blood glucose, triglycerides, and total cholesterol. No significant
differences in serum level of Rai1+/- and WT mice. Data reported as mean  s.e.m.
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III. Metabolic signaling from adipose tissue to hypothalamus

In order to fully understand the role of obesity in SMS, it is critical that the pathways that
control hunger and obesity are examined in detail to determine the involvement of reduced levels
of RAI1. To determine the biochemical mechanism in the Rai1+/- mice and in the SMS patients,
it is necessary to have an understanding of the mechanism of energy intake and expenditure by
the body, as well as all of the key players that regulate it. Fat stores and their signaling to the
brain play an important role in helping to regulate food intake, and this satiety pathway is of
interest for the study of obesity in the Smith-Magenis syndrome phenotype.
Fat cells of adipocytes in the body produce leptin which is a hormone involved in
energy intake. Leptin travels to the brain where it interacts with the leptin receptor in the arcuate
nucleus (ARC) of the hypothalamus.36 Once bound to the leptin receptor, a class I cytokine
receptor, STATs are activated by phosphorylation and travel into the nucleus to transcribe
important gene products such as POMC.36 POMC is pro-opiomelanocortin, a pro-hormone, that
is shown to cause obesity if it is deficient.36 The lateral hypothalamus consists of mainly two
types of neurons that are involved in appetite and satiation. One type expresses both
neuropeptide Y (NPY) and Agouti related peptide (AgRP), and these neurons are responsible for
stimulating feeding and inhibiting satiation. The other type of neuron expresses propropiomelanocortin (POMC), as well as cocaine- and amphetamine- regulated transcript (CART)
and is responsible for inhibiting feeding and stimulating satiation.37 It is known that these
neurons are regulated by leptin and that any changes in leptin affect the obesity of the animal.
Leptin is known to stimulate the POMC/CART neurons while thought to inhibit the NPY/AgRP
neurons by inducing depolarization and increasing neuron firing.37 Leptin also reduces the
release of GABA from the NPY neurons.38 GABA is another neurotransmitter released from the
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NPY/AgRP neurons that inhibits the POMC/CART neurons and was not significant between
Rai1+/- and WT mice.39 Once a stimulated neuron transcribes POMC, it is then cleaved into the
peptide α-melanocyte stimulating hormone which, in turn, stimulates the melanocortin pathway
through the MC4 receptor, causing satiation. Mutations in the melanocortin 4 receptor are
known to cause early onset obesity in humans as well as mice.40
The NPY/AgRP neuron is known to be inhibited by leptin but, in turn, is stimulated by
ghrelin. Ghrelin is a hormone produced in the hypothalamus and acts in an opposite way to
leptin. Ghrelin is elevated when there is need for energy intake, and the NPY/AgRP neurons are
activated causing release of AgRP and NPY, in turn stimulates food intake.41 NPY and AgRP
inhibit the melanocortin receptor pathway.42 Disruptions in this feeding/satiety pathway lead to
obesity including leptin deficient ob/ob mice and it is clear that Smith-Magenis syndrome and
the insufficient amount of RAI1 also cause this pathway to be disrupted. Previous data indicate
that leptin is increased in Rai1+/- mice compared to WT littermates.31 This leptin elevation
should stimulate satiety and yet, data demonstrate reduced satiety in the Rai1 haploinsufficient
mice compared to their WT littermates.
There are two possible reasons for the elevation of leptin. Leptin may be upregulated
as it should be in mice with surplus adipose tissue and there is a lost signal somewhere
downstream, or the mouse is leptin resistant.43 To further illuminate the involvement of leptin
and how it affects other genes in the satiety pathway, a microarray analysis was done on mouse
hypothalamus that uncovered several genes that are involved in obesity that are dysregulated in
the transgenic and heterozygous mice.31 Two of these genes are Pomc and Bdnf. Along with
mRNA expression levels of obesity related genes, it is important to analyze circulating hormones
and peptides that are involved in the obesity and satiety pathway as well.
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Serum levels of circulating hormones and peptides
Adiponectin, a hormone secreted by adipose tissue that breaks down fatty acids and
regulates glucose, is not significantly upregulated in the Rai1+/- mice compared to WT controls
.31,45 Serum levels of ghrelin, PYY, adiponectin, and amylin, IGF-1, corticosterone, and ACTH
are important in determining where in the satiety pathway Rai1 is acting. Adiponectin a
hormone secreted by adipose tissue and is thought to make the POMC/CART neurons more
sensitive to insulin and has been shown to break down fatty acids and regulate glucose.45
Amylin is a hormone that is secreted by the pancreas and has been shown to help induce weight
loss in diet-induced obese mice and Rai1+/- have elevated serum levels of amylin that are not
significantly different from WT mice (Figure 6a).46 Ghrelin is known to stimulate the
NPY/AgRP neurons to facilitate food intake and is significantly elevated in Rai1+/- mice at above
30 weeks of age (p=0.0059, Figure 6b).41 Protein YY, which is released by the gastrointestinal
tract and suppresses appetite in humans, was also found to be not significantly different in the
Rai1+/- animals(Figure 6c, data collected, in part, by Brooke Burns).46 Insulin-like growth
factor 1(IGF-1) is secreted by the liver and mimics insulin as it binds to the insulin receptor. The
release of IGF-1 is regulated by growth hormone which was found to be a gene dysregulated in a
hypothalami microarray, however IGF-1 is not significantly different in Rai1+/- and WT mice
(Figure 6d).31 Corticosterone is a hormone involved in the regulation of metabolism and was
significantly increased in the Rai1+/- mice (Figure 6e). The significance of these results are
unclear as corticosterone is also involved in stress responses and there is no way for us to
quantify the stress of a mouse while collecting serum. Adrenocorticotropic hormone (ACTH) is
secreted by the pituitary gland and can be cleaved into α-MSH, which is a POMC neuron
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signaling molecule and is also not significantly elevated in the Rai1+/- mice (Figure 6f). No
differences were found when comparing any serum level by age, sex, or weight.
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Figure 6. Serum levels of hormones involved in satiety and energy metabolism. Levels of
amylin, ghrelin, PYY, IGF-1, corticosterone, and ACTH. All mice were fasted for serum
collection. Data are reported with mean s.e.m. *P < 0.05, **P<0.001.
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Expression Studies in Rai1+/- mice
In order to identify genes that are involved in the disrupted circuits that result in
hyperphagia and obesity, mRNA expression levels were looked at to determine where Rai1 may
be acting in this pathway. Data show a significant decrease in mRNA expression of Brainderived neurotrophic factor (Bdnf) in Rai1+/- mice.31 When Bdnf is selectively knocked-down,
the mice are obese and hyperphagic.47 Cholecystokinin (Cck), which regulates food intake and
weight gain was not significantly different in Rai1+/- and WT mice.48 Npy expression in Rai1+/mice was also not significantly different.31
Proopiomelanocortin (Pomc) is expressed in many tissues, including the skin, lymphoid
system, anterior pituitary, and the arcuate nucleus of the hypothalamus.49 Pomc is a precursor of
melanocortins that are involved in energy homeostasis such as melanocyte-stimulating hormones
(MSHs) and adrenocorticotrophin (ACTH).50 Mutations in Pomc have been associated with
obesity in both human and mice.50,51 Previously determined Elsea lab microarray data
demonstrated that Pomc was down regulated ~5.0 fold in Rai1+/- mice. Q-PCR confirmed the
down regulation observed in the Rai1+/- mice (p<0.0001, Figure 7a).
The melanocortin 4 receptor (Mc4r) is a G-protein coupled receptor that interacts with
α-MSH and has been shown to be involved with feeding behavior and energy expenditure.52
Mice with deletions of Mc4r exhibit an obesity phenotype, as well as hyperphagia and
hyperleptinemia.52 Expression data shown here reveal that Mc4r expression is upregulated ~
2.25 fold in the Rai1+/- mice (p = 0.0071, Figure 7b). AgRP neurons express both AgRP and
NPY that are strong signaling molecules that increase hunger.53 Once Agrp, is released it
suppresses satiety signaling, as it is an antagonist to both MC3 and MC4 receptors.54 Agrp
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neurons also release the neurotransmitter GABA which directly can inhibit the action of the
POMC neuron.39 The AgRP neuron is necessary for enabling the feeding pathways as ablation
of the neuron causes starvation.55 Expression data shown here reveal that Agrp expression is
down regulated in the Rai1+/- mice (p< 0.0001, Figure 7c).
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Figure 7. mRNA expression studies. Expression studies of Pomc, Mc4r, and Agrp were
analyzed in hypothalami. There were no expression differences based on age, weight, or gender.
Data are reported with mean  s.e.m. n ≥ 4. *P < 0.05, ***P<0.0001.
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Discussion
The preceding data demonstrate the hyperphagia and lack of satiety seen in the Rai1+/mice that contribute to the obesity phenotype. It may be of interest to determine if there is a
signaling disconnect or a repetitive and learned behavior by evaluating pups that are raised by
Rai1+/- and WT mothers and compare their eating behaviors. It is possible that the mice are
learning their eating behaviors from their mothers. The data also show that the increased adipose
tissue within the abdomen of the Rai1+/- does not have increased cell size or different cell shape.
These results suggest that there are adipose stem cells within the adipose tissue are proliferating
and therefore further analysis needs to be performed, including proliferation marker
immunohistochemistry in order to fully understand how the adipose tissue is regulating feeding
behavior and metabolism.
Adiposity is an important risk factor associated with metabolic syndrome. It is clear
that the Rai1+/- mice, though they are obese and have females have increased abdominal fat, do
not have metabolic syndrome. Triglycerides and cholesterol as well as blood glucose were not
significantly different in Rai1+/- mice when compared to WT mice. These findings clearly
suggest that this SMS obesity phenotype does not cause metabolic syndrome when taken
together with the previous data showing no elevation in insulin in the Rai1+/- mice.
In the future, microarray analysis of adipose tissue to determine genes dysregulated
would suggest other Rai1 targets important in hunger and satiety. Adipose tissue secretes
hormones such as adiponectin and leptin which signal satiety through the melanocortin 4
pathway, and it is important to determine if these specific genes are expressed and regulated
differently within adipose tissue when compared to hypothalamic microarray data.
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Figure 8 demonstrates the differences in expression of various regulators of hunger
and satiety found in the Rai1+/- mice. Although we would expect that increased leptin would
result in elevated levels of Pomc, this is not the case in the Rai1+/- mice, the lowered Pomc
expression may result from leptin resistance as mentioned earlier, or a down regulation of leptin
receptors on the surface of the POMC neuron to account for the increased flood of leptin
signaling.56 In order to determine which is the case, expression of the leptin receptor will have to
be explored. In this pathway, it would also be expected that AgRP would be elevated to increase
eating if the POMC signaling was not inhibiting the AgRP. Perhaps the answer to this lies in the
overexpression of the MC4 receptor. An increase in this receptor would suggest elevated ligand
levels from the satiety signaling cascade (α-MSH) which should cause satiety in the Rai1+/- mice.
This is likely not the case, as Pomc is decreased and α-MSH is likely decreased as well. The
MC4 receptor may be elevated in response to a decreased level of α-MSH so as to be able to bind
more ligand and cause a larger signaling response. It is interesting that ACTH, a precursor to αMSH, is not significantly different amongst Rai1+/- mice. The serum results of IGF-1, PYY, and
amylin suggest normal satiety signaling, but more expression data will have to be collected from
other players in the satiety pathway such as the orexins and endocannabinoid system to fully
understand the meaning of all of these data.
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Figure 8. Mechanistic pathway of satiation in the hypothalamus of Rai1+/- mice. Significant
increases in expression or serum level indicated with green arrow and significant decreases with
a red arrow. All conclusions derived from studies reported herein with Rai1+/- mice..
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Chapter 3: Ampakine treatment of Rai1+/- mice
Introduction
As described earlier, Bdnf expression is significantly decreased in the Rai1+/- mice
compared to WT mice. Bdnf and the TrkB receptor that it binds to, are shown to be downstream
of the melanocortin pathway and play important roles in hunger and satiety.57 Data show that
deficiency of Bdnf in mice causes hyperphagia, hyperactivity, obesity, and hyperactivity.58
Hyperphagia, severe obesity, impaired cognitive function, and hyperactivity are associated with
functional loss of one copy of the brain-derived neurotrophic factor (BDNF) gene in humans.58
Data also show that patients and mice with Huntington disease have reduced levels of Bdnf.59
Ampakines are a class of drug that bind to the AMPA receptor and promote improved
memory and attention span by increasing the release of glutamate.60 Glutamate is an important
neurotransmitter involved in learning and memory.60 Data show that ampakines increase the
expression of Bdnf.61 This attribute makes ampakines candidate drugs for treatment of
Alzheimer disease, Huntington disease, ADHD, and schizophrenia. The ability of ampakines to
increase the expression of Bdnf also makes this drug a candidate for increasing the expression of
Bdnf in Rai1+/- mice, which may decrease hyperphagia and the prevalence of obesity in these
mice.62
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Materials and Methods
Ampakine drug preparation. Cortex ampakine CX1837 was used at a concentration of 0.5
mg/ml. These ampakine drugs do not easily dissolve in water so 2-Hydroxypropyl-βcyclodextrin (HPCD) powder was dissolved with equal weights of water and 0.9% injectable
saline as a 1:1:1 mixture, or 33% HPCD in water/0.045% saline. The solution was heated to 37C
and then submerged in a sonicator to aid solubilization. The resulting solution is a clear viscous
liquid. Once HPCD powder was dissolved, the total volume was split in half. Ampakine
CX1837 was added to half of the volume, and the remaining half was used as vehicle.

Ampakine injection. Each mouse was weighed daily and given 1 mg/kg of ampakine CX1837
twice daily. This was the suggested high dose for CX1837 by Cortex. The volume of drug was
altered once a week to account for weight fluctuations in the mice. The mice were injected
intraperitoneally without the use of an anesthetic or sedative. Each mouse received each dose in
the same order every day.

Mouse dosing. Mice were separated into dosage groups by genotyping using weight and
craniofacial characteristics. The four groups included wild type vehicle treated, wild type drug
treated, Rai1+/- vehicle treated, and Rai1+/- drug treated.

Physical Testing:

Weight gain. Mice were weighed on a daily basis to determine if there was any weight gain or
loss due to drug administration.
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Blood glucose. Blood was taken from the tip of each mouse tail using a needle stick and
measured using capillary test strips and an Easy Pro glucometer. All glucose samples were taken
after a 12 or 24 hour fast.

Righting. Mice were turned on their backs and the time it took for the mouse to right itself was
recorded in seconds.

Whisker Response. The whiskers of a freely moving mouse were lightly brushed with a small
paint brush while head turning and sudden stop in moving were recorded.

Sensorimotor and Reflexes:

Postural reflex. Mice were place in an empty cage and the cage was shaken from right to left for
10 seconds and up and down for 10 seconds. The ability of the mouse to remain in an upright
position was measured visually.

Response to being picked up by tail. Mice were picked up by the base of their tail and held for
10 seconds. The mouse was then lowered to the ground. Limb extension upon lowering to
ground, as well as head raising were measured visually.

Gaiting test. Mice had every foot painted a different color with non-toxic paint. The mouse was
then placed onto a white sheet of paper and walked through a small tunnel. The gaiting was
measured from 3 individual steps that were then averaged together. This was done to determine
stride, sway, and stance. Stride is the distance between two back or front feet. Sway is the
distance of the mouse paws from side to side and stance is the diagonal distance between two
front or back paws.
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Drop test. Mice were dropped from a height of 15 cm with painted feet and the distance between
their two back paws was measured.

Hot-plate test. Mice were placed on an analgesic hot plate that was heated to 55°C for a
maximum of 30 seconds. The time it took for a mouse to display a common heat response was
recorded in seconds. A common heat response included jumping, paw raising and paw licking
and shaking.

Rotorod test. Mice were placed on a stationary rotorod prior to the start of rotation. The rotorod
is a rotating cylinder 7” long and 9” in circumference that is covered with cloth tape to ensure a
better grip. Progressive rotations occur that double each minute. Upon rotation, the rotorod
completes 4 rotations within the first minute and 8 within the second minute, and so on. Each
mouse was placed on the rotorod prior to drug administration for a baseline reading and again at
days 5 and 12. Total number of seconds mouse remained on rotorod prior to falling were
recorded. Testing performed by Mary Tokarz.

Behavioral Tests:

Food consumption Food was weighed daily throughout the drug administration. Mice were
placed in isolated cages with a predetermined amount of normal chow (5% fat) and an unlimited
amount of water. Food was weighed every 24 hours.

Nest building assessment: Mice were placed in fresh cages and given nesting materials. The
quality and depth of each nest is determined in time intervals of 30, 60 and 90 minutes. Nests
were assessed for fluffiness, amount chewed and mouse movement. After 90 minutes the depth
of the thickest part of the nests was taken.
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Tube test. Two mice were placed in a small tube at opposite ends that was 30 cm x 3.5 cm. The
mice were allowed to interact with one another. None of the mice had ever lived together
before, but it was noted if the mice were siblings. The mice were assessed for dominance and
submission on the basis that a more dominant mouse would force the other mouse back out of
the tube.

Motor activity chamber. Mice were placed in an activity chamber and their activity was
measured for 30 minutes. The chamber used in this study consisted of 8”x9” Plexiglas chambers
fixed with photo beam sensors on aluminum sides that were located above stainless steel barred
floors. Each mouse was placed in the chamber prior to drug administration for a baseline
reading and again at days 5 and 12. Data were recorded as total beam breaks. Testing performed
by Mary Tokarz.

Operant responding test. For operant response tests, eight standard mouse operant conditioning
chambers that were sound- and light-attenuated (MED Associates, St. Albans, VT) were used.
Each operant conditioning chamber (18 x 18 x 18 cm) was equipped with a house light, two
levers (left and right), and a recessed food pellet receptacle centered between the levers. Fan
motors provided ventilation and masking noise for each chamber. House lights were illuminated
during sessions. A computer with Logic „1‟ interface (MED Associates) and MED-PC software
(MED Associates) controlled schedule contingencies and maintained data. A hopper delivered
food pellets into the receptacle and a food pellet was released every time the right lever was
pressed. Mice were placed in the box and allowed to lever press for three 15 minute sessions
throughout the course of the study. One of these sessions was prior to drug administration, while
two sessions followed at days 5 and 12. For the final test on day 16, mice were fasted overnight
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and then placed in the chamber for 1 hour. Data were recorded as total number of bar presses.
Testing performed by Mary Tokarz.
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Results
Neurological Testing
Of the 29 mice that were used in this study, 16 of them were Rai1+/- mice and the
remaining 13 were WT. Of the 16 Rai1+/- mice, 8 of them received vehicle and 8 of them
received drug. The WT animals were separated into groups where 6 of them were injected with
vehicle while 7 were injected with drug. There were two age groups of mice at 7 and 16 weeks.
It is important to note that Rai1+/- C57Bl/6J background mice have difficulty breeding and have
reduced transmission of the mutant allele, so the C57Bl/6J mice were crossed with the FVB/N
strain and their 50:50 progeny were used in this study. It is also important to mention that each
of the mice were placed through every battery of tests in the same order. All testing done during
this study was also performed when the drug was at its peak in the mice unless they are labeled
as baseline readings and were taken before drug administration.
The most basic neurological testing included righting, whisker response, and postural
reflex. These tests were performed in order to ensure that the dose of the drug was not sedating
the mice so that the accuracy of the other testing could be guaranteed. The mice all corrected
themselves instantaneously when placed on their backs regardless of if they were receiving
vehicle or drug (Table 1). All mice remained upright during the postural reflex testing both
when the cage was shaken up and down as well as side - to - side (Table 1). Upon being picked
up by the base of the tail, all 29 mice raised their heads and reached for the ground upon
lowering which is the normal response (Table 1).
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Table 1: Data of reflexes and behavior testing in ampakine treated Rai1+/- and WT mice.
WT
Vehicle
n=6
Sensorimotor reflexes and simple
reflexes (% abnormal)
Righting reflex
Postural reflex
Response to being picked up by tail
Whisker response
Behavioral assessment
Tube test (number of wins)
*Nest building after 90 minutes (%
with)
No chew
Partial chew
Fluffy nest
Flat nest
*Nesting statistics done using a two-tailed
Fisher's exact test

WT
Drug
n=7

Rai1+/Vehicle
n=8

Rai1+/Drug
n=8

0
0
0
0

0
0
0
0

0
0
0
0

0
0
0
0

0

0

0

0

33
33
17
17

29
29
29
14

25
38
25
13

25
38
25
13

The gaiting test was performed on each mouse, and their feet were painted different
colors. There was no difference between any of the groups for stride, sway, or stance even when
accounting for age( Figure 9a, b, c). There was also no significant difference between any of
the drug or vehicle groups for the drop test( Figure 9d). Previous data collected in mice with a
C57Bl/6J background indicated that the Rai1+/- mice have a significantly larger landing splay
(Santhosh Girirajan‟s dissertation, 2008). This mixed background does not appear to have that
phenotype.
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Figure 9. Gaiting tests and drop test of ampakine and vehicle injected mice. Statistical
analysis performed using a student t-test. All data reported as mean  s.e.m.

A hot plate test was performed to determine if the ampakine treatment could correct the
delayed response to pain. It is shown that the Rai1+/- mice can tolerate a significantly longer time
on the hot plate than their WT littermates (p<0.0001, Figure 10). It is also demonstrated that
when given ampakine, Rai1+/- mice recover from the insensitivity to pain phenotype and have
quicker pain responses that cause them to spend considerably less time on the hot plate than
Rai1+/- vehicle mice, yet the Rai1+/- drug treated mice are significantly higher than the WT
ampakine treated littermates (p<0.0001, p = 0.0209, Figure 10).
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Figure 10. Hot plate test of ampakine and vehicle treated Rai1+/- and WT mice. Maximum
time for each mouse to be on the hot plate was 20 seconds. All data reported as mean  s.e.m.
*P< 0.05, ***P< 0.0001.

Other neurological tests included the rotorod and the locomotor box. Although neither of
these tests were significant between any of the groups, there was a slight trend that suggested all
of the mice genotypes and treatment groups show decreased movement the longer they are
treated with ampakine or vehicle (Figure 11a, b). This was indicated by fewer beam breaks.
These results mimic a trend seen in previous Elsea lab data; however, the WT mice are not
significantly above the Rai1+/- mice, as in the previous Elsea lab data(Santhosh Girirajan‟s
dissertation, 2008). This may be due to the change in background, as the previous data was
collected using C57Bl/6J and the studies presented here were done with the mixed background
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mentioned earlier. There is also a trend in the rotorod testing suggesting that the Rai1+/- mice
treated with ampakine tended to hang on to the rotorod longer and not fall as quickly, even
though these results were not significant.

Rotorod
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Figure 11. Rotorod and motor activity of ampakine and vehicle treated Rai1+/- and WT
mice. Data collected prior to treatment and at day 5 and day 12 of ampakine treatment. All data
reported as mean  s.e.m; n ≤ 6. Statistics for these data were done using a mixed effects
repeated measures ANOVA with a pairwise analysis.
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Behavioral Testing
The mice were each observed for 5 minutes in a new cage. The amount of times each
mouse wild ran, froze, sniffed, licked, reared, or huddled were recorded (Figure 12). It was
suspected that the Rai1+/- mice would rear less than their WT littermates, as previously
described.63 All of the above listed behaviors were not significantly different in any of the
genotypes or treatment groups. The mice spent the majority of those five minutes sniffing and
digging in their new surroundings. Although it was expected that Rai1+/- mice that are drug
treated would have increased movement and explore more frequently than Rai1+/- vehicle treated
mice, there were no significant differences.
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Figure 12. Behavioral testing over a 5 minute period of ampakine treated WT and Rai1+/mice. Each mouse was observed for a 5 minute period in a clean cage and behaviors were
recorded. Behaviors included: freezing, wild running, sniffing, licking, rearing, and huddling.
Data is reported as mean ± s.e.m.

It was observed during the tube test that none of the mice were aggressive or dominant
(Table 1). In most instances the mice sniffed each other and then passed each other in the tube
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exiting the other side. None of the mice forced another mouse out of the tube. It is important to
note that every mouse pair were siblings, however, were not caged together. The nest building
test was inconclusive as the mice that had the largest nest depth and those that did not chew their
pads were not in any one specific group (Table 1). Insufficient nest building may not be a
behavior associated with Rai1+/- haploinsufficiency and there may be several other factors,
including the estrus cycle in females that can change the instinct to nest build. Another test used
to measure behavior was an operant test in which the mice learn to push a lever to receive food.
It was predicted that if the ampakine was decreasing the amount of food intake, that the Rai1+/mice would be less likely to press the bar for pellets than their vehicle treated Rai1+/- siblings.
This was not the case. The only group that was significantly different from any other, were the
Rai1+/- mice who received ampakine drug evaluated at Day 16. These mice pushed the bar
significantly more than their baseline reading prior to drug administration (p = 0.0016, Figure
13). A trend suggests that drug treated mice, regardless of genotype, pushed the bar more
frequently to receive food pellets.
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Figure 13. Operant test of ampakine and vehicle treated Rai1+/- and WT mice. Operant data
evaluated as bar presses/minute as the mice did not spend the same amount of time in the operant
box for each day of treatment. All data reported as mean  s.e.m. Statistics for these data were
done using a mixed effects repeated measures ANOVA with a pairwise analysis and a
Bonfferoni corrected p-value of 0.0021.

Feeding Behavior

Over the course of the 16 day study, daily food and weights were taken of each mouse.
Mice growth curves from the ampakine pilot study were compared to the a normal WT
Bl/6:FVB/N 50:50 growth curve (Figure 14). The mice had few significant changes in weight
over the course of the study (Figure 15a, b, c, d). Mice were separated by age group and
gender. At day 1 of ampakine treatment, the 7 week old female Rai1+/- and WT drug treated
mice had significantly different weights (p = 0.0211, Figure 15a). The 7 week old female Rai1+/47

and WT vehicle treated mice were also significantly different at day 1 of the treatment (p =
0.0056, Figure 15a). At day 1 of ampakine treatment, the 16 week old female Rai1+/- and WT
drug treated mice had significantly different weights (p = 0.0074, Figure 15c). Male Rai1+/- and
WT mice had no significant differences in weight at 7 or 16 weeks of age (Figure 15b, d). It is
interesting to note that the trends for the vehicle and drug treated Rai1+/- mice in the 16 week old
age group were the same. The trend indicates that all of the mice in each of the dosage groups
stayed at approximately the same weight throughout the study in contrast to the normal growth
curve. The Rai1+/- ampakine treated mice should steadily increase in weight from 16-18 weeks
if there is no drug affect as the normal growth curve suggests. These data do not suggest that the
Rai1+/- are gaining steady amounts of weight. The mice also had few significant shifts in eating
habit except at day 10 when all of the mice consumed more food (Figure 15e, f, g, h). Female
Rai1+/- vehicle and drug treated mice, that were 7 weeks of age, ate significantly different
amounts of food at day 1 and day 9 of ampakine treatment (p = 0.0192, p = 0.0369, Figure 15e).
Drug treated Rai1+/- and WT males ate significantly different amounts of food at day 13 of the
ampakine treatment (p = 0.0454, Figure 15f). Drug and vehicle treated Rai1+/- females had
significantly different amounts of food consumed at day 1, day 3, day 5, and day 13 of the
ampakine treatment (p = 0.0074, p = 0.0105, p = 0.0049, p = 0.0125, Figure 15g). These
differences may be due, in part, to the food crumbling seen in the drug treated Rai1+/- females.
This behavior may have changed the measurement of food, as it may have skewed the actual
amount of food consumed, indicating the mice had eaten more without subtracting the extra food
from the bottom of the cage. Rai1+/- ampakine treated mice reduced food crumbling as the study
progressed.
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Male Rai1+/- mice, that were 16 weeks old, did not eat significantly different amounts of
food than their WT male littermates (Figure 15h). These data do not have any consistent trends
and suggest that the ampakine treatment in not altering food consumption. The mice were
fasted day 8 - 9 in order to collect blood glucose levels and account for slight elevations in food
consumption.
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Figure 14. Growth curve of C57Bl/6J:FVB/N mice by gender. Body weights for WT and
Rai1+/- mice from 3-26 weeks. a) Growth data of female Rai1+/- and WT mice. b) Growth data
of male Rai1+/- and WT mice. Data reported as mean ± s.e.m; n ≥ 1. *P < 0.05.
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Figure 15. Food consumption and weight of ampakine and vehicle treated Rai1+/- and WT
mice. Data were separated by gender and by age group. a, c) Weights of 7 and 16 week old
ampakine and vehicle treated female mice. b, d) Weights of 7 and 16 week old ampakine and
vehicle treated male mice. e, g) Food consumption of 7 and 16 week old ampakine and vehicle
treated female mice. f, h) Food consumption of 7 and 16 week old ampakine and vehicle treated
male mice. All data reported as mean  s.e.m; n ≥ 1. *P < 0.05.

Blood glucose evaluated in the mice at day 10 and day 14 of the study, after 24 and 12
hour fasts, respectively. It is interesting to note that we have fasted several other mice for blood
glucose testing previously and the mice have shown very little stress, yet and the mice in this
study were weak and did not tolerate the fast well. This may be due to the dextrin in the HPCD
powder, as the mice may experience altered levels of glucose when they are injected as dextrin is
a polymer of D-glucose. WT mice that were ampakine and vehicle treated have normal levels of
glucose, while the Rai1+/- ampakine and vehicle treated mice had lower levels of blood glucose.
Blood glucose was elevated significantly in the WT mice that were administered drug compared
to the Rai1+/- mice receiving ampakine (p = 0.0285, Figure 15). The mice were injected twice a
day with an HPCD (dextrin) powder containing solution that may have altered their normal
blood glucose levels. Mice that are treated with a highly branched cylcodextrin show a steady
blood glucose.64 The cyclodextrin is processed more slowly than glucose and the mean blood
glucose levels were lower in the cyclodextrin treated mice.64 This data suggest that the ampakine
treated Rai1+/- mice are more sensitive to cyclodextrin as their blood glucose is significantly
lower than WT ampakine treated mice. The HPCD powder may not be the best reagent to aid in
the dissolution of ampakine.
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Figure 16. Blood glucose of ampakine and vehicle treated Rai1+/- and WT mice. All data
reported as mean  s.e.m. *P < 0.05.
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Discussion
Upon completion of this pilot ampakine study, the food consumption was expected to be
decreased as the ampakine drug increased Bdnf expression. The ampakine drug was also
expected to prevent the Rai1+/- mice from becoming obese, as the 16 week old mice were at an
age when their weights should have begun to increase at a significantly steeper slope than the
WT mice. As this project is an Elsea group effort, hypothalami from these mice will need to be
checked for expression levels of Bdnf to ensure that our method of delivery and dosing were
correct. Much of the other data were inconclusive, and this indicates that the study was ended
too abruptly and a longer administration of ampakine is required. This study contained many
tests that were performed to ensure that the mice were not becoming sedated from the drug.
Reflex data including the whisker test, righting, and postural reflex, were not significantly
different between the genotype or treatment groups and suggest the ampakine treatment did not
affect neurological functioning.
The dose that was given to the mice in this pilot study was the maximum high dose
suggested for this particular Cortex ampakine. It may be of interest to try other ampakines
available from Cortex to see if they work more effectively. It may also be that two weeks is not
enough time to see significant changes in our Rai1+/- mouse model of SMS.
In the future, I propose that this study be repeated with a longer time of administration of
the ampakine. It is also important to test untreated mice with this battery of neurological and
behavioral tests to compare the mixed background results with the previous Elsea lab data, as the
results were inconsistent. There may be a background effect that has to be taken into
consideration and therefore other mouse backgrounds can be tried.
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Conclusions and future plans
Rai1+/- mice are hyperphagic and do not have a significant satiation response compared
to their WT littermates. Rai1+/- mice crumble food in their cages as well as demonstrate
repetitive behaviors that contribute to the amount of food consumed. Along with hyperphagia,
Rai1 haploinsufficient mice are obese by 20 weeks of age and Rai1+/- females have a
significantly increased amount of abdominal fat compared to WT females. Along with no
significant differences in adipose tissue H&E staining, these data suggest that adipose stem cells
in the obese mice are proliferating.
Obesity and abdominal fat are risk factors for metabolic syndrome, however, data
suggest that the Rai1+/- mice do not have metabolic syndrome. Blood glucose levels,
triglycerides, and total cholesterol levels are not significantly different between Rai1+/- and WT
mice. Rai1+/- mice appear to be a healthy model of obesity.
Satiety signaling is an important aspect that contributes to Rai1+/- obesity. Elevated
levels of leptin in the Rai1+/- mice should be activating the POMC neuron increasing satiety.
Rai1+/- mice continue to eat significant amounts of food and the leptin signal may not be
effectively reaching the POMC neuron. Leptin resistance, as well as reduced numbers of POMC
neurons could account for the leptin signaling disconnect. Increased levels of ghrelin after the
Rai1+/- mice reach 30 weeks of age may be responsible to continued feeding because ghrelin
signals the AgRP/NPY neurons to induce hunger and feeding. High levels of Mc4r suggest that
the receptor may be upregulated to increase ligand intake from decreased levels of α-MSH due to
decreased Pomc expression. The increased levels of Mc4r should cause an increase in Bdnf
expression. Rai1+/- mice have decreased levels of Bdnf suggesting that Rai1 acts directly on
Bdnf expression and contributes to metabolism regulation.31
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Treating Rai1+/- mice with a drug that increases Bdnf expression should decrease
hyperphagia and obesity. During a pilot study, Rai1+/- mice treated with ampakine did not appear
to lose weight or consume less food. Blood glucose was only significantly different between WT
and Rai1+/- drug treated mice. The hot plate test was the only significant neurological data which
suggest the ampakine treatment had an effect on Rai1+/- mice neurological deficits. This test may
have been the only significant data because polymorphisms in the different mouse backgrounds
could affect Rai1 haploinsufficiency phenotypes making it difficult to access the ampakine
effectiveness.

Future directions for Aim 1
In the future, it is important to elaborate on satiety and obesity using varying diets to
determine if fat formation and location are dependent upon type of food consumed. Imaging
techniques may be used to determine fat distribution as well as glucose uptake and metabolism.
Testing adipose tissue for proliferation will also enable researchers to elucidate any differences in
adipose cells between Rai1+/- and WT mice. To help conclude if food consumption is a repetitive
behavior, toys can be placed in the mouse cages to evaluate if food crumbling and hyperphagia
are decreased. Microarray analysis of adipose tissue will assist in finding genes within adipose
tissue that are differentially expressed and may play a role in hormone satiety signaling from
adipose tissue to the brain. The satiety signaling pathway is very complicated and requires
continued research on signaling targets downstream of the melanocortin pathway to pursue other
factors involved in the obesity of Rai1+/- mice. Other pathways of interest may include orexins
and endocannabinoids.
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Future directions for Aim 2
The 50:50 Bl/6:FVB/N background Rai1+/- mice did not share the same phenotypes as
the Bl/6 Rai1+/- mice, therefore, it may be important to breed the Rai1+/- mutant into other
backgrounds to illuminate the phenotypic changes of Rai1 haploinsufficiency associated with
varying mouse backgrounds. Treating the mice for longer than 2 weeks may elucidate long term
effects of ampakine drugs. If ampakines increase expression of Bdnf, it is possible that a
feedback loop in the satiety pathway would lead to changes in expression of Pomc, Mc4r, Npy,
and Agrp. Expression studies would be useful in determining the specific role of Bdnf in the
satiety pathways.
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